"10.1371_journal.pone.0080437","plos one","2013-11-11T00:00:00Z","Anita K Gandhi; Tao Shi; Mingyu Li; Ulf Jungnelius; Alfredo Romano; Josep Tabernero; Salvatore Siena; Peter H Schafer; Rajesh Chopra","Department of Translational Development, Celgene Corporation, Summit, New Jersey, United States of America; Department of Scientific Information Systems, Celgene Corporation, San Diego, California, United States of America; Department of Biostatistics and Programming, Celgene Corporation, Summit, New Jersey, United States of America; Clinical Research and Development, Celgene, Summit, New Jersey, United States of America; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; Ospedale Niguarda Ca' Granda, Milan, Italy","Conceived and designed the experiments: UJ AR JT SS. Analyzed the data: AKG TS ML. Wrote the paper: AKG RC. Trial design and conduct: UJ AR JT SS. Intellectual input and data analysis support: PS.","Anita Gandhi, Tao Shi, Mingyu Li, Ulf Jungnelius, Alfredo Romano, Peter Schafer, and Rajesh Chopra are employees of Celgene Corporation, whose company funded this study. Salvatore Siena is a member of advisory boards for Sanofi-Aventis, AstraZeneca, Roche, Genentech, Celgene, Genomic Health, Bayer, and Amgen. Josep Tabernero has participated in advisory boards for Amgen, Celgene, Genentech, Merck-Serono, Novartis, Roche, Sanofi- Aventis, and Symphogen. Lenalidomide (Revlimid®) is a marketed Celgene product. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.","2013","11","Anita K Gandhi","AKG",9,TRUE,4,NA,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
